Scott A. Armstrong, MD, PhD

Director, Memorial Sloan Kettering Leukemia Center; Vice Chair for Basic and Translational Research, Department of Pediatrics; Grayer Family Chair
Pictured: Scott Armstrong

I am a pediatric oncologist who is interested in developing new therapies that are less toxic and more effective.

The work in my lab has led to several findings that point to potential new therapies for children and adults with leukemia. We have made fundamental discoveries demonstrating that leukemias are related to, but distinct from, normal blood stem cells and are defined by dependence on stem cell–associated pathways activated in an inappropriate developmental context. We have also recently identified changes in DNA structure as a critical initial step in leukemia development. This has led to the discovery of small molecules that can reverse this process and eradicate leukemia cells. These studies have led to the development of new therapeutic approaches that are now being tested in patients.

Appointments for New Patients
Clinical Expertise

Pediatric Leukemia; New Therapies; Cancer Biology

Languages Spoken

MD, PhD, University of Texas Southwestern Medical School


Boston Combined Residency Program in Pediatrics, Children’s Hospital of Boston


Children’s Hospital of Boston; Dana-Farber Cancer Institute/Harvard Medical School

Board Certifications

Pediatric Hematology-Oncology

Publications by Scott A. Armstrong
Visit PubMed for full listing of Scott A. Armstrong journal articles
Pubmed is an online index of biomedical articles maintained by the U.S. National Library of Medicine and the National Institutes of Health.
View Scott A. Armstrong's laboratory research.